-transparent.png){kind=logo}
Mouse mammary carcinoma FM3A cells deficient in thymidine kinase were transformed by a cloned gene for herpes simplex virus type 1 thymidine kinase. Among several anti-herpetic nucleoside analogues, (E)-5-(2-bromovinyl)-2'-deoxyuridine, (E)-5-(2-iodovinyl)-2'-deoxyuridine and (E)-5-(2-bromovinyl)-2'-deoxycytidine inhibited the growth of the transformed cells at concentrations 5000- to 20000-fold lower than those required to inhibit the growth of the corresponding wild-type cells. The selective inhibitory action of these compounds was due to a specific phosphorylation by the viral thymidine kinase. From the transformed cells, thymidine-auxotrophic mutants that are deficient in thymidylate synthase were isolated. These mutant cell lines should prove useful in elucidating the mechanism of action of the antiherpetic nucleoside analogues.
J Balzarini, and
E De Clercq, and
D Ayusawa, and
K Shimizu, and
T Seno
September 1983,
Virology,
J Balzarini, and
E De Clercq, and
D Ayusawa, and
K Shimizu, and
T Seno
April 1990,
Biochemical Society transactions,
J Balzarini, and
E De Clercq, and
D Ayusawa, and
K Shimizu, and
T Seno
May 2001,
Cancer gene therapy,
J Balzarini, and
E De Clercq, and
D Ayusawa, and
K Shimizu, and
T Seno
January 1991,
Intervirology,
J Balzarini, and
E De Clercq, and
D Ayusawa, and
K Shimizu, and
T Seno
July 1994,
The Journal of general virology,
J Balzarini, and
E De Clercq, and
D Ayusawa, and
K Shimizu, and
T Seno
April 1995,
Acta virologica,
J Balzarini, and
E De Clercq, and
D Ayusawa, and
K Shimizu, and
T Seno
April 1987,
Molecular pharmacology,
J Balzarini, and
E De Clercq, and
D Ayusawa, and
K Shimizu, and
T Seno
May 1984,
Antimicrobial agents and chemotherapy,
J Balzarini, and
E De Clercq, and
D Ayusawa, and
K Shimizu, and
T Seno
April 1982,
Journal of clinical microbiology,
J Balzarini, and
E De Clercq, and
D Ayusawa, and
K Shimizu, and
T Seno
June 1989,
Biochemical pharmacology,
